Ardea Biosciences Inc RDEA:NASDAQ
Sector: Healthcare Industry: Biotechnology & Drugs
22.21 Arrow Up0.55   2.54% 54,182 Market data is delayed by at least 20 minutes.
Last Change  /  % Change Volume
Exclusive
Features
 
When you open a Scottrade account, you will be able to trade, add stocks to a watch list, set alerts and get real-time quotes. Or
 
1day |  5day |  6mo |  1yr |  5yr

Latest News Headlines for Ardea Biosciences Inc

Earlier Headlines - view recent headlines
--/--

Bid/Size

--/--

Ask/Size

21.99

Price Open

21.66

Previous Close

22.36

Day High

21.66

Day Low

1.04

Beta (5yr)

27.78/4/21/10

52wk High/Date

12.18/11/19/09

52wk Low/Date

508.3 Million

Market Capitalization

22.9 Million

Shares Outstanding

50.94

Volatility Avg (1 Year)

89.7 Thousand

Avg Vol (10 day)

NM

P/E Ratio

-1.59

EPS (TTM)

Ardea Biosciences Inc does not pay dividends.

Scottrade Customers

Get the following exclusive content at no additional cost with your Scottrade account:

  • Standard & Poor's STARS Rating for the featured stock
  • Research reports from Reuters and Standard & Poor's
  • Market Edge Second Opinion Weekly Report

For full analysis, Open an Account or Log In with Scottrade

Ardea Biosciences Inc vs. Peers

Company Market Cap YTD Price Performance
RDEA

Ardea Biosciences Inc

508.3M
+58.6%
VRX

Valeant Pharmaceuticals International

4.6B
+88.7%
HRBR

Harbor BioSciences, Inc.

9.5M
-49.3%
IDIX

Idenix Pharmaceuticals, Inc.

436.7M
+178.6%

Company Background

Ardea Biosciences, Inc. is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus (HIV). The Company's product portfolio includes RDEA594, An inhibitor of the URAT1 kidney transporter for the treatment of hyperuricemia and gout; RDEA684, A next generation URAT1 transporter inhibitor for the treatment of hyperuricemia and gout; RDEA119, A MEK inhibitor for the treatment of cancer; RDEA806, A NNRTI for the treatment of HIV, and RDEA427, A next generation NNRTI for the treatment of HIV.

© 2010 Scottrade

Brokerage Products and Services offered by Scottrade, Inc. - Member FINRA and SIPC

Online market and limit stock trades are just $7 for stocks priced $1 and above.

Any specific securities, or types of securities, used as examples are for demonstration purposes only. No information on this Web site should be considered a recommendation or None of the information provided should be considered a recommendation or solicitation to invest in, or liquidate, a particular security or type of security.

Investors should consider the investment objectives, risks, and charges and expenses of a mutual fund carefully before investing. A mutual fund's prospectus contains this and other information about the mutual fund. Prospectuses are available through our trading site or through a Scottrade branch office. The prospectus should be read carefully before investing. No transaction fee (NTF) funds are subject to the terms and conditions of the NTF funds program. Scottrade is compensated by the funds participating in the NTF program through recordkeeping, shareholder, or SEC 12b-1 fees.

Investors should consider the investment objectives, charges, expense, and unique risk profile of an Exchange Traded Fund (ETF) carefully before investing. Leveraged and Inverse ETFs may not be suitable for long-term investors and may increase exposure to volatility through the use of leverage, short sales of securities, derivatives and other complex investment strategies. A prospectus contains this and other information about the ETF and should be obtained from the issuer. The prospectus should be read carefully before investing.

Margin trading involves interest charges and risks, including the potential to lose more than deposited, or the need to deposit additional collateral in a falling market. Margin Disclosure Statement (PDF) is available for download, or it is available at one of our branch offices. It contains information on our lending policies, interest charges, and the risks associated with margin accounts.

Options involve risk and are not suitable for all investors. Detailed information on our policies and the risks associated with options can be found in the Scottrade Options Application and Agreement, Brokerage Account Agreement, and by downloading the Characteristics and Risks of Standardized Options and Supplements (PDF) from The Options Clearing Corporation, or by requesting a copy from your local branch office. Supporting documentation for any claims will be supplied upon request.

Market volatility, volume, and system availability may impact account access and trade execution.

Testimonials may not be representative of the experience of other clients and are no guarantee of future performance or success.